Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Morus nigra*, commonly known as the black mulberry, is a botanical extract being investigated for its therapeutic potential in oral health, specifically for the treatment of periodontal diseases. In clinical research, it is formulated as a mouthwash and used as an adjunct to non-surgical periodontal treatments such as scaling and root planing (SRP). The extract is noted for its antimicrobial properties against subgingival plaque pathogens, including red complex bacteria and *Fusobacterium*. Additionally, it exhibits anti-inflammatory effects by modulating the levels of pro-inflammatory cytokines in the gingival crevicular fluid, specifically reducing tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), while potentially increasing anti-inflammatory markers like interleukin-10 (IL-10).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morus nigra.